203 related articles for article (PubMed ID: 16797686)
1. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance.
Bristow RE; Purinton SC; Santillan A; Diaz-Montes TP; Gardner GJ; Giuntoli RL
Gynecol Oncol; 2006 Nov; 103(2):709-13. PubMed ID: 16797686
[TBL] [Abstract][Full Text] [Related]
2. Recurrence patterns and surveillance for patients with early stage endometrial cancer.
Salani R; Nagel CI; Drennen E; Bristow RE
Gynecol Oncol; 2011 Nov; 123(2):205-7. PubMed ID: 21820709
[TBL] [Abstract][Full Text] [Related]
3. Is cytologic screening an effective surveillance method for detection of vaginal recurrence of uterine cancer?
Cooper AL; Dornfeld-Finke JM; Banks HW; Davey DD; Modesitt SC
Obstet Gynecol; 2006 Jan; 107(1):71-6. PubMed ID: 16394042
[TBL] [Abstract][Full Text] [Related]
4. Costs and benefits of routine follow-up after curative treatment for endometrial cancer.
Agboola OO; Grunfeld E; Coyle D; Perry GA
CMAJ; 1997 Oct; 157(7):879-86. PubMed ID: 9327795
[TBL] [Abstract][Full Text] [Related]
5. Could follow-up different modalities play a role in asymptomatic cervical cancer relapses diagnosis? An Italian multicenter retrospective analysis.
Zola P; Fuso L; Mazzola S; Piovano E; Perotto S; Gadducci A; Galletto L; Landoni F; Maggino T; Raspagliesi F; Sartori E; Scambia G
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S150-4. PubMed ID: 17868785
[TBL] [Abstract][Full Text] [Related]
6. Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma.
Berchuck A; Anspach C; Evans AC; Soper JT; Rodriguez GC; Dodge R; Robboy S; Clarke-Pearson DL
Gynecol Oncol; 1995 Oct; 59(1):20-4. PubMed ID: 7557610
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practice.
Santillan A; Govan L; Zahurak ML; Diaz-Montes TP; Giuntoli RL; Bristow RE
Gynecol Oncol; 2008 Jun; 109(3):388-93. PubMed ID: 18405946
[TBL] [Abstract][Full Text] [Related]
8. Post treatment surveillance of type II endometrial cancer patients.
Zakhour M; Li AJ; Walsh CS; Cass I; Karlan BY; Rimel BJ
Gynecol Oncol; 2013 Dec; 131(3):609-12. PubMed ID: 24051222
[TBL] [Abstract][Full Text] [Related]
9. Glandular cells in vaginal cytology Papanicolaou tests in patients with hysterectomy for endometrial adenocarcinoma.
Steele E; Umar SA; Bomeisl P; Miedler J; Zanotti KM; Wasman JK; Hunt DC; Abdul-Karim FW
Diagn Cytopathol; 2012 Feb; 40(2):138-40. PubMed ID: 20891002
[TBL] [Abstract][Full Text] [Related]
10. Posttherapy surveillance of women with cervical cancer: an outcomes analysis.
Bodurka-Bevers D; Morris M; Eifel PJ; Levenback C; Bevers MW; Lucas KR; Wharton JT
Gynecol Oncol; 2000 Aug; 78(2):187-93. PubMed ID: 10926801
[TBL] [Abstract][Full Text] [Related]
11. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme.
Reddoch JM; Burke TW; Morris M; Tornos C; Levenback C; Gershenson DM
Gynecol Oncol; 1995 Nov; 59(2):221-5. PubMed ID: 7590477
[TBL] [Abstract][Full Text] [Related]
12. Detecting Asymptomatic Recurrence in Early-Stage Endometrial Cancer: The Value of Vaginal Cytology, Imaging Studies, and CA-125.
Lee JY; Kim JH; Seo JW; Kim HS; Kim JW; Park NH; Song YS
Int J Gynecol Cancer; 2016 Oct; 26(8):1434-9. PubMed ID: 27465903
[TBL] [Abstract][Full Text] [Related]
13. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients.
Sartori E; Pasinetti B; Carrara L; Gambino A; Odicino F; Pecorelli S
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S241-7. PubMed ID: 17826824
[TBL] [Abstract][Full Text] [Related]
14. Routine endometrial sampling of asymptomatic premenopausal women shedding normal endometrial cells in Papanicolaou tests is not cost effective.
Kapali M; Agaram NP; Dabbs D; Kanbour A; White S; Austin RM
Cancer; 2007 Feb; 111(1):26-33. PubMed ID: 17262796
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of a test to detect metastases for endometrial cancer.
Havrilesky LJ; Maxwell GL; Chan JK; Myers ER
Gynecol Oncol; 2009 Mar; 112(3):526-30. PubMed ID: 19100608
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.
Rankins NC; Secord AA; Jewell E; Havrilesky LJ; Soper JT; Myers E
Gynecol Oncol; 2007 Aug; 106(2):388-93. PubMed ID: 17509672
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of the treatment for intermediate risk endometrial cancer: postoperative brachytherapy vs. observation.
Fanning J; Hoffman ML; Andrews SJ; Harrah AW; Feldmeier JJ
Gynecol Oncol; 2004 Jun; 93(3):632-6. PubMed ID: 15196856
[TBL] [Abstract][Full Text] [Related]
18. Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.
Orr JM; Barnett JC; Leath CA
Gynecol Oncol; 2011 Sep; 122(3):501-4. PubMed ID: 21714992
[TBL] [Abstract][Full Text] [Related]
19. Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.
Tergas AI; Havrilesky LJ; Fader AN; Guntupalli SR; Huh WK; Massad LS; Rimel BJ
Gynecol Oncol; 2013 Sep; 130(3):421-5. PubMed ID: 23747836
[TBL] [Abstract][Full Text] [Related]
20. A comparison of symptomatology, physical examination, and vaginal cytology in the detection of recurrent cervical carcinoma after radical hysterectomy.
Soisson AP; Geszler G; Soper JT; Berchuck A; Clarke-Pearson DL
Obstet Gynecol; 1990 Jul; 76(1):106-9. PubMed ID: 2359555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
